Healthcare Stocks Rise as Investors Rotate Away From Tech
AbbVie, Eli Lilly, and J&J are nearing all-time highs as investors rediscover the appeal of biopharma.
If you've been watching your tech-heavy portfolio sweat lately, you're not alone — and it looks like a growing number of investors are quietly moving their money somewhere a little more stable. Healthcare stocks, particularly in the biopharmaceutical space, are suddenly the cool kids on the block again.
Shares of AbbVie, Eli Lilly, and Johnson & Johnson were all on track to reach all-time highs on Friday, which is a pretty loud signal that Wall Street's appetite for the sector is making a comeback. When multiple giants in the same industry push toward record territory on the same day, that's not a coincidence — that's a rotation.
Read more ON Semiconductor Tumbles to Worst Day Since 2020 After Synaptics Deal →
So what's a rotation, exactly? Think of it like a playlist shuffle. Investors aren't necessarily bailing on stocks altogether; they're just swapping out one genre — say, high-flying, high-risk tech names — for something that feels steadier, like big pharma companies with reliable revenue streams and dividends. Healthcare has historically been considered a "defensive" sector, meaning it tends to hold up better when the broader market gets choppy.
The timing makes sense. Tech stocks have faced pressure from rising interest rates, valuation concerns, and general economic uncertainty. Meanwhile, biopharma companies like Eli Lilly have been buoyed by blockbuster drug pipelines — Lilly in particular has seen massive investor enthusiasm around its diabetes and weight-loss treatments. AbbVie and J&J bring their own stability to the table with diversified product portfolios and strong cash flows.
Whether this shift sticks or is just a short-term trade is the real question — but for now, healthcare is clearly having its moment. Continue reading at MarketWatch.com
